Contact
searchSearch
HMP Global
Login

Major Depressive Disorder News

Study on MDD - stock image
News
Phase II Trial of AL001 for MDD Set to Begin Later this Year
03/24/2025
Plans have been announced for a phase II clinical study of investigational lithium therapy AL001 for MDD, focusing on its unique properties and its effect on lithium delivery in the brain compared with marketed lithium salts.
Plans have been announced for a phase II clinical study of investigational lithium therapy AL001 for MDD, focusing on its unique properties and its effect on lithium delivery in the brain compared with marketed lithium salts.
Plans have been announced for a...
03/24/2025
Psych Congress Network
Pill bottle
News
Investigational MDD Drug Shows Favorable Outcome in Interim Analysis
02/18/2025
An ongoing phase 2b trial investigating adjunctive ALTO-300 in patients with MDD and inadequate antidepressant response will add 50 participants after results from a planned interim analysis showed favorable findings, Alto Neuroscience...
An ongoing phase 2b trial investigating adjunctive ALTO-300 in patients with MDD and inadequate antidepressant response will add 50 participants after results from a planned interim analysis showed favorable findings, Alto Neuroscience...
An ongoing phase 2b trial...
02/18/2025
Psych Congress Network
Major Depressive Disorder MDD
News
Hypomanic Symptoms in Major Depression Linked With Treatment Resistance
01/03/2025
Common in patients with unipolar depression, hypomanic symptoms are associated with both treatment-resistant depression and reduced remission of suicidal thoughts, according to a study in the Journal of Affective Disorders.
Common in patients with unipolar depression, hypomanic symptoms are associated with both treatment-resistant depression and reduced remission of suicidal thoughts, according to a study in the Journal of Affective Disorders.
Common in patients with unipolar...
01/03/2025
Psych Congress Network
depression stock photo
News
Mitophagy-Related Genes in Astrocytes May Serve as MDD Biomarkers
12/05/2024
A trio of newly identified mitophagy-related genes in astrocytes are promising biomarkers for diagnosing and treating MDD, according to a study in the Journal of Affective Disorders.
A trio of newly identified mitophagy-related genes in astrocytes are promising biomarkers for diagnosing and treating MDD, according to a study in the Journal of Affective Disorders.
A trio of newly identified...
12/05/2024
Psych Congress Network
Depression
News
Study Reveals Anhedonia Impact on Symptom Severity and Treatment Outcomes in Patients With MDD
11/22/2024
A study presented in a poster at Psych Congress 2024 in Boston, Massachusetts, aimed to understand the characteristics and treatment patterns of patients with MDD who experience prominent anhedonia compared to those who do not or who have low...
A study presented in a poster at Psych Congress 2024 in Boston, Massachusetts, aimed to understand the characteristics and treatment patterns of patients with MDD who experience prominent anhedonia compared to those who do not or who have low...
A study presented in a poster at...
11/22/2024
Psych Congress Network
Patient survey
News
Patient Survey Identifies Barriers to TD Treatment
11/06/2024
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive...
11/06/2024
Psych Congress Network
depression stock photo
News
Add-on Lumateperone Eases MDD in Patients With Inadequate Antidepressant Response
11/04/2024
Adjunctive treatment with the atypical antipsychotic lumateperone improved depressive symptoms and severity more than adjunctive placebo in patients with MDD with inadequate response to previous antidepressant therapy, according to a poster...
Adjunctive treatment with the atypical antipsychotic lumateperone improved depressive symptoms and severity more than adjunctive placebo in patients with MDD with inadequate response to previous antidepressant therapy, according to a poster...
Adjunctive treatment with the...
11/04/2024
Psych Congress Network
Psilocybin
News
Psilocybin May Improve Outcomes More Than Traditional MDD Treatments
10/08/2024
While intensive treatments with psilocybin and the serotonin reuptake inhibitor (SSRI) escitalopram were associated with long-term improvements in major depressive disorder (MDD) symptom severity, recent phase 2 double-blind, randomized,...
While intensive treatments with psilocybin and the serotonin reuptake inhibitor (SSRI) escitalopram were associated with long-term improvements in major depressive disorder (MDD) symptom severity, recent phase 2 double-blind, randomized,...
While intensive treatments with...
10/08/2024
Psych Congress Network
brain netw
News
Patients With Specific Treatment-Resistant Depression Biotype Improve With TMS
09/05/2024
Patients with a particular cognitive biotype of treatment-resistant depression are more likely to experience improvement with TMS compared with other patients, study finds.
Patients with a particular cognitive biotype of treatment-resistant depression are more likely to experience improvement with TMS compared with other patients, study finds.
Patients with a particular...
09/05/2024
Psych Congress Network
Doctor and patient
News
Clinician-Level Differences Significantly Affect MDD Prescribing, Outcomes
08/01/2024
Antidepressant prescribing patterns and outcomes for patients with MDD vary significantly between prescriber groups, suggest study findings published in JAMA Psychiatry.
Antidepressant prescribing patterns and outcomes for patients with MDD vary significantly between prescriber groups, suggest study findings published in JAMA Psychiatry.
Antidepressant prescribing...
08/01/2024
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Sign Up

Psych Congress Network Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use